TY - JOUR T1 - Locus Coeruleus Integrity from 7T MRI Relates to Apathy and Cognition in Parkinson’s Disease and Progressive Supranuclear Palsy JF - medRxiv DO - 10.1101/2021.04.19.21255762 SP - 2021.04.19.21255762 AU - Rong Ye AU - Claire O’Callaghan AU - Catarina Rua AU - Frank H. Hezemans AU - Negin Holland AU - Maura Malpetti AU - P. Simon Jones AU - Roger A. Barker AU - Caroline H. Williams-Gray AU - Trevor W. Robbins AU - Luca Passamonti AU - James Rowe Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/27/2021.04.19.21255762.abstract N2 - Background and Objectives The loss of noradrenergic neurons in the locus coeruleus (LC) contributes to various cognitive and neuropsychiatric symptoms in Parkinson’s disease (PD) and progressive supranuclear palsy (PSP). The spatial precision of in vivo LC imaging is improved using a magnetisation transfer sequence combined with ultra-high field 7T MRI. This study aimed to test the sensitivity of LC imaging in PD and PSP, to characterise the spatial pattern of LC atrophy in patients, and its relationship to cognition and apathy.Methods This cross-sectional observational study recruited patients with idiopathic PD, probable PSP-Richardson’s syndrome and age-matched healthy controls (HC) via specialist clinics and volunteer registries. All participants underwent clinical assessments for cognition and apathy, and high-resolution (0.08 mm3) LC scans. To quantify LC integrity, the contrast-to-noise ratio (CNR) relative to a pons reference region was calculated and extracted using a probabilistic atlas. Subregional mean CNRs were summarised to test group differences and to correlate LC integrity with apathy and cognition scores. LC clusters were identified to confirm the spatial pattern of the effect (threshold free cluster enhancement, 10000 permutations, p<0.05, corrected for family-wise error).Results Twenty-five patients with PD, 14 with PSP and 24 controls with completed dataset were included in the study. Patients with PSP were more impaired on global cognition and apathy scores, compared to controls and PD. Clusters with reduced contrast were observed in the caudal LC for both PD and PSP patients relative to controls (HC>PD, right caudal LC, 37 voxels; HC>PSP, bilateral caudal LC, 206 voxels). PSP and PD patients showed similar levels of LC degeneration, but this was more extensive in PSP. Across both disease groups, LC integrity was associated with cognitive performance (MoCA: F(1,37)=5.339, p=0.027, bilateral LC, 200 voxels; ACE-R: F(1,37)=4.297, p=0.045, left LC, 70 voxels) and apathy (Apathy Scale: F(1,37)=4.335, p=0.044, left LC, 99 voxels).Discussion We confirm the sensitivity of 7T LC imaging to detect sub-regional LC changes in PD and PSP. The relationship between LC integrity and non-motor symptoms highlights the potential for noradrenergic therapeutic strategies to ameliorate cognitive and behavioural features of PD and PSP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Parkinson's UK (K-1702); the Cambridge Centre for Parkinson-Plus; the China Scholarship Council; a Neil Hamilton Fairley Fellowship from the Australian National Health and Medical Research Council (GNT1091310); a Cambridge Trust Vice-Chancellor's Award and Fitzwilliam College Scholarship; the Association of British Neurologists - Patrick Berthoud Charitable Trust (RG99368); the Medical Research Council (SUAG/051 G101400; MR/P01271X/1); James S. McDonnell Foundation 21st Century Science Initiative Scholar Award in Understanding Human Cognition; the Wellcome Trust (103838); a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1); the NIHR Cambridge Clinical Research Facility and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local Cambridge Research Ethics Committees (REC reference: 10/H0308/34) and all participants provided written informed consent according to the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe MT and MP2RAGE data used in this study are available for non-commercial academic purposes upon request. ER -